Payment overview · 2025
General Payments
$453.04
22 reported records · 15 companies
Healthcare provider profile · identity verified
Michael Joe Whiteley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TOMBALL, TX · NPI 1295720795
Verified facts
What the public records show
CMS Open Payments records show Michael Joe Whiteley, D.O. received $453.04 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.56 | 24.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.04 | 10.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.82 | 8.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.77 | 8.6% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.65 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.95 | 5.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.86 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.76 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.24 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.39 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.84 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.59 | 3.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.12 | 3.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.92 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.53 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $453.04 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.56 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 65 |
| Gabapentin | Gabapentin | 135 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 52 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 111 | 40 |
| Lisinopril | Lisinopril | 109 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 46 |
| Losartan Potassium | Losartan Potassium | 104 | 45 |
| Metformin Hcl | Metformin Hcl | 96 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 29 |
| Potassium Chloride | Potassium Chloride | 88 | 31 |
| Furosemide | Furosemide | 84 | 35 |
| Omeprazole | Omeprazole | 67 | 24 |
| Allopurinol | Allopurinol | 64 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 32 |
| Finasteride | Finasteride | 54 | 25 |
| Alendronate Sodium | Alendronate Sodium | 50 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 22 |
| Ezetimibe | Ezetimibe | 48 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 20 |
| Metformin Hcl Er | Metformin Hcl | 45 | 17 |
| Clonidine Hcl | Clonidine Hcl | 43 | 12 |
| Atenolol | Atenolol | 42 | 19 |
| Montelukast Sodium | Montelukast Sodium | 40 | 16 |
| Trazodone Hcl | Trazodone Hcl | 39 | 13 |
| Eliquis | Apixaban | 37 | 15 |
| Famotidine | Famotidine | 37 | 12 |
| Carvedilol | Carvedilol | 35 | 12 |
| Glipizide Er | Glipizide | 34 | 13 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 11 |
| Simvastatin | Simvastatin | 33 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Celecoxib | Celecoxib | 31 | 16 |
| Azithromycin | Azithromycin | 27 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.04 · 22 records | ABBVIE INC. | AIRSUPRA, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Korlym, LAGEVRIO, OTEZLA, REPATHA, REXULTI, TZIELD, Tymlos, VRAYLAR, XYOSTED | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error